

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE
HELD ON THURSDAY 11th JUNE 2015 AT 2.00PM
PENRITH RUGBY CLUB**

Present:	Bill Glendinning Lesley Angell Pauline Bourne Andrea Loudon Ben Merriman Dr Andrea Mulgrew Sarah Roberts Dr Julia Smith Dr Amanda Pugh Tim Slaughter Phil Utting	Chief Pharmacist, NCUHT (Chair) Medicines Optimisation Team Lead, NECS Senior Pharmacist, UHMBT Clinical Pharmacy Lead, CCG LPC Representative GP Prescribing Lead, Allerdale Locality Patient Voice representative GP Prescribing Lead, South Lakes Locality GP Prescribing Lead, Furness Locality Medicines Optimisation Pharmacist, NECS Senior Technician, Medicines Optimisation, NECS
----------	--	---

In Attendance:

25/15 **APOLOGIES FOR ABSENCE** *Action*

Apologies for absence were received from:
 Helen Huck, Lead Pharmacist CPFT
 Dr Charlotte Asquith, GP, Carlisle, LMC Representative

26/15 **DECLARATION OF INTERESTS**
 None

27/15 **MINUTES OF THE PREVIOUS MEETING**

The minutes of the previous meeting held on 30th April 2015 were agreed.

28/15 **ACTION LOG FROM PREVIOUS MEETING (30 April 2015)**

Updates were given as follows:
 14/013 – this action is completed
 15/01 – this action is completed
 15/03 – this action is completed
 15/10 – this action is completed
 15/11 – this action is completed
 15/14 – this action is completed
 15/18 – this action is completed

69/14 – DMARDS Monitoring

This is on the agenda under DMARD Shared Care Protocols – item 9.7

PB

70/14 – Revised Dosing for Domperidone use in babies and children position statement

ACTION : Manchester Paediatric Consultant now drafting guideline for approval. No timescale at present. ONGOING.

PB

85/14 – Primary Care Management of Cellulitis AL to attend second meeting in July 2015. ONGOING.	AL
107/14 & 19/15 – Comments on Draft PPI's Algorithm PB to feedback the APC comments. Concerns over the prescribing of Gaviscon Advance or Peptac. Prescribing of an Alginate requested instead of a brand. ONGOING.	PB
111/14 – Proposal for the use of NOACS for cardioversion. Approved by Lancs North CCG APC, PB to forward papers to the group. ONGOING.	PB
114/14 - Bring proposal for dementia patients reviews as part of the SCG Darren Reynolds will attend the next meeting, has been given the date for August APC. ONGOING.	HH
134/14 – Draft a statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decision of the IFR panel. Statement to be passed to Rheumatologists as part of Blueteq. ONGOING.	AL TS
15/15- Nabilone Red drug at present. PB would like it to be black. Status to be reviewed for newly prescribed patients. PB to write a paper as to reasons for changing to Black.	TS PB
16/15 Branded Generics The APC supported the paper in principle but requested rewording the statement to stress generic prescribing with specified exemptions. ACTION: Statement to be brought to the next meeting. ONGOING.	TS
20/15 – Sick Day Medication AQA Document is thought to be too detailed and is not being used by UHMBT. Waiting for new national document to be published. ONGOING.	PB
21/15 – Mycophenolate mofetil Amendment to be made to SC guideline for UHMBT. Noted that blood test are to be done by primary care. ONGOING.	PB
33/15 - NICE CG Medicines Optimisation Base line assessment to be completed at next APC. ONGOING.	ALL
34/15 – Contract Monitoring BG to meet with TS to complete the set up of Dermatology on Bluteq. ONGOING.	BG TS

29/15 **RECENT LJF NEW DRUG RECOMMENDATIONS**

Levonorgestrel (Jaydess)– Contraception for up to 3 years. GREY – TS to check

Collagenase - Treatment of adult men with Peyronie’s disease. BLACK

Insulin degludec – Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year. BLACK

Levonorgestrel (Levosert) – Contraception, heavy menstrual bleeding. GREY (new application to be made).

Acclidinium + formoterol – Maintenance bronchodilator - BLACK

31/15 **NICE TECHNOLOGY APPRAISALS**

TA339 Omalizumab – Previously treated chronic spontaneous urticarial. RED

TA340 Ustekinumab – Active psoriatic arthritis. RED

TA341 Apixaban – Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. GREEN

TA342 Vedolizumab – Moderate to severe ulcerative colitis. RED

TA343 Obinutuzumab – Untreated chronic lymphocytic leukaemia (in combination with chlorambucil) RED

TA344 Ofatumumab – Untreated chronic lymphocytic leukaemia (in combination with chlorambucil or bendamustine) RED

32/15 **NICE CLINICAL GUIDELINES**

CG97 Lower urinary tract symptoms in men; assessment and management

LA

LA to look at a pathway for men to be developed.

NG8 Anaemia management in people with chronic kidney disease.

No change noted.

NG9 Bronchiolitis in children

Noted.

NG10 Violence and aggression: short term management in mental health and community settings.

Noted.

NG11 Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges.

Noted.

52/15 **Topical Ketoprofen** - ScriptSwitch message to be added to advise prescribers not to prescribe. LA to contact PC.

LA

35/15 **MEDICINES SAFETY**

BG

Medicines safety officers’ forum, meeting to be arranged with all the officers to create a formal network. BG to ask HH for a safety officer update from CPFT.

40/15	LIOTHYRONINE	
	To be brought to the August meeting.	
53/15	North of England Guidance on the use of long acting antipsychotic injections.	
	Approved by CPFT MMC, minor amendments to be made then the document will be circulated.	HH
54/15	NTAG- RITUXIMAB FOR IMMUNE THROMBOCYTOPENIC PURPURA	
	This drug has been agreed North of Tyne but not agreed in Northumberland. TS to add drug to Blueteq. AL to check if drug is CCG commissioned. ONGOING – to be discussed ay next meeting.	TS AL
55/15	NTAG- AIRSONETT LAMINAR FLOW DEVICE FOR TREATMENT OF UNCONTROLLED ASTHMA	
	Not recommended by NTAG – Decision accepted.	
56/15	PENTOSAN POLYSULFATE – RAG CLASSIFICATION BLACK	
		TS
57/15	PRESCRIBING OF SEVELAMER & LANTHANUM, PRIMARY OR SECONDARY CARE?	
	BG to provide AL with financial impact report, AL to feedback at next meeting with regards to shared care? ONGOING	BG AL
58/15	ORAL CONTRACEPTIVES & ACNE	
	Supported. Noted that the choice of agent should be based upon the VTE risk rather than the use of acne treatment.	
59/15	DMARD SHARED CARE PROTOCOLS	
	Methotrexate – recommended to move to Two monthly monitoring regardless of complexity. All other SCG can move to Three monthly monitoring. Noted that any changes made by the Consultant, the GP must be notified. BG to take approved SCG to NCUHT. ACCEPTED.	
60/15	DUORESP	
	Accepted that this should be prescribed by brand. Noted that adequate training for both staff and patient’s is required. APPROVED.	

61/15	INFLIXIMAB BIOSIMILARS	PB
	<p>PB is to meet with UHMBT Consultants July 15, papers will then be circulated to members.</p> <p>Noted that the NTAG guidance will recommend the use of infliximab biosimilars for new patients although switching will be at the discretion of the consultant.</p> <p>Note that NICE recommends the use of infliximab biosimilars for UC.</p> <p>Gain share discussions will take place with the respective commissioning & contracts teams.</p>	
62/15	SUPPLY OF IV ANTIBIOTICS IN THE COMMUNITY	BG
	<p>Agreed that pathways for administration of IV antibiotics in the community need to be developed although unclear which organisation is the lead provider. Mainly prescribed by the NCUHT and administered by CPFT community nursing teams. BG to raise the question in his organisation. ONGOING.</p>	
63/15	PRACTICE QUALITY FRAMEWORK	
	For information only.	
64/15	ORAL NUTRITIONAL SUPPLEMENTS	
	<p>Not endorsed.</p> <p>To be returned and a Cumbria wide document produced endorsed by all the trusts.</p>	
65/15	OPERATIONAL	
	Viola has now retired; she was formally thanked for her contribution to the APC.	
66/15	DRUG SAFETY UPDATE	TS
	<p>April – Prescription Pad & PMM’s updated with information regarding Hydroxyzine and Codeine.</p> <p>Insulin degludec – not approved by LJF on the basis of non-submission by the company. BG had received requests for two patients which have been rejected.. However, it was reported that CPFT Cumbria Diabetes Service does prescribe insulin degludec. Updated NICE diabetes guidelines are due later this year. NICE evidence summary states that insulin degludec is comparable to insulin glargine. BG to request clinicians prepare a formulary application.</p> <p>May - noted</p>	BG
67/15	FOR INFORMATION	
	<p>Minutes received:</p> <p>Palliative Care MMG (1st Oct 14) – No comments</p> <p>Palliative Care MMG (11th March 15) – No comments</p>	
68/15	ANY OTHER BUSINESS	

Updated **Infant feeds guidelines**: “Endorse ACBS” relating to Colief to be removed following guidance from the DOH.
ENDORSED.

BG reported that the company who promote Apremilast are offering free supply prior to NICE approval. It was agreed that this offer should not be accepted. The APC reinforced their position that new drugs will not be reviewed pre-nice.

BG formally thanked TS for all his work with the APC as TS retires at the end of July.

DATE and TIME of next meeting

Thursday, 13th August 2015, 2pm at Enterprise House, Kendal
